Furazabol
Unique Japanese compound synthesized in the 1960s with a furazan (1,2,5-oxadiazole) ring fused to the A-ring. Historically used for hyperlipidemia as well as anemia — one of the few AAS that actually lowers LDL cholesterol rather than raising it. Used by several Eastern Bloc athletes in the 1980s-90s.
Mechanism of Action
DHT-derived with the 2,3-furazan ring modification. Does not aromatize. 17α-methylated for oral bioavailability. The furazan ring uniquely alters lipid metabolism — documented LDL reduction mechanism via hepatic lipase modulation, distinct from typical AAS lipid effects. Moderate AR agonism with reasonable anabolic:androgenic selectivity.
Typical Dosing
⚠ Warning Flags
- •Very rare outside Japan — significant counterfeiting risk
- •Limited modern clinical data
Effect Profile
Side Effect Profile
Research Studies
Anabolic and androgenic effects of furazabol and its effect on serum lipids
Yamamoto I, et al. · 1969
Original pharmacological characterization of furazabol showing anabolic:androgenic ratio of ~3.7:1 (Hershberger) with the unique finding of LDL cholesterol reduction — contrasting with other AAS of the era that universally worsened lipid profiles.